Literature DB >> 25117906

Erlotinib and gastric acid-reducing agents: a combination to avoid or to support?

T H Oude Munnink1, J H Schouwink2, H B B Colen1, K L L Movig1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25117906     DOI： 10.1038/clpt.2014.164

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  2 in total

1.  Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.

Authors:  Roelof W F van Leeuwen; Frank G A Jansman; Nicole G Hunfeld; Robert Peric; Anna K L Reyners; Alex L T Imholz; Jacobus R B J Brouwers; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

2.  EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.

Authors:  Nesaretnam Barr Kumarakulasinghe; Nicholas Syn; Yu Yang Soon; Atasha Asmat; Huili Zheng; En Yun Loy; Brendan Pang; Ross Andrew Soo
Journal:  Oncotarget       Date:  2016-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.